Anaptysbio (NASDAQ: ANAB) revenue
Anaptysbio reported revenue of $234.6m for fiscal 2025, 157.0% more than in fiscal 2024 ($91.3m). Since fiscal 2016 its revenue has grown by 1,306.2%, an average growth of 34.1% a year.
Anaptysbio has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2022, −83.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $234.6m | +157.0% | $226.9m | 96.7% |
| 2024 | $91.3m | +432.0% | $66.2m | 72.5% |
| 2023 | $17.2m | +66.8% | −$164.4m | −958.3% |
| 2022 | $10.3m | −83.7% | −$115.2m | −1,119.4% |
| 2021 | $63.2m | −15.8% | −$56.8m | −89.9% |
| 2020 | $75.0m | +837.5% | −$23.9m | −31.8% |
| 2019 | $8.0m | +60.0% | −$107.4m | −1,342.9% |
| 2018 | $5.0m | −50.0% | −$66.7m | −1,334.4% |
| 2017 | $10.0m | −40.1% | −$28.8m | −287.8% |
| 2016 | $16.7m | — | −$3.0m | −18.1% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Anaptysbio revenue compared with its sector
By revenue for its latest fiscal year, Anaptysbio ranks 240th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Anaptysbio, 157.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 238th | OrthoPediatrics | $236.3m | 15.4% |
| 239th | Akebia Therapeutics | $236.2m | 47.5% |
| 240th | Anaptysbio | $234.6m | 157.0% |
| 241st | Cerus | $233.8m | 16.1% |
| 242nd | Puma Biotechnology | $228.4m | −0.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Anaptysbio
- How much revenue did Anaptysbio make in fiscal 2025?
- Anaptysbio reported revenue of $234.6m for fiscal 2025, compared with $91.3m in fiscal 2024.
- How much has the revenue of Anaptysbio grown?
- Between fiscal 2016 and fiscal 2025 it went from $16.7m to $234.6m: 1,306.2% more, an average growth of 34.1% a year.
- What was the best year for revenue at Anaptysbio?
- Of its last 10 fiscal years, fiscal 2025, with $234.6m.
- Where does Anaptysbio rank in its sector by revenue?
- It ranks 240th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Anaptysbio come from?
- From the annual report (Form 10-K) that Anaptysbio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Anaptysbio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Anaptysbio: the Anaptysbio page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.